Skin manifestations of COVID-19 in children: Part 3.

Détails

ID Serval
serval:BIB_CC27183B0285
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
Skin manifestations of COVID-19 in children: Part 3.
Périodique
Clinical and experimental dermatology
Auteur⸱e⸱s
Andina D., Belloni-Fortina A., Bodemer C., Bonifazi E., Chiriac A., Colmenero I., Diociaiuti A., El-Hachem M., Fertitta L., van Gysel D., Hernández-Martín A., Hubiche T., Luca C., Martos-Cabrera L., Maruani A., Mazzotta F., Akkaya A.D., Casals M., Ferrando J., Grimalt R., Grozdev I., Kinsler V., Morren M.A., Munisami M., Nanda A., Novoa M.P., Ott H., Pasmans S., Salavastru C., Zawar V., Torrelo A.
Collaborateur⸱rice⸱s
ESPD Group for the Skin Manifestations of COVID-19
ISSN
1365-2230 (Electronic)
ISSN-L
0307-6938
Statut éditorial
Publié
Date de publication
04/2021
Peer-reviewed
Oui
Volume
46
Numéro
3
Pages
462-472
Langue
anglais
Notes
Publication types: Journal Article ; Review
Publication Status: ppublish
Résumé
The current COVID-19 pandemic is caused by the SARS-CoV-2 coronavirus. The initial recognized symptoms were respiratory, sometimes culminating in severe respiratory distress requiring ventilation, and causing death in a percentage of those infected. As time has passed, other symptoms have been recognized. The initial reports of cutaneous manifestations were from Italian dermatologists, probably because Italy was the first European country to be heavily affected by the pandemic. The overall clinical presentation, course and outcome of SARS-CoV-2 infection in children differ from those in adults as do the cutaneous manifestations of childhood. In this review, we summarize the current knowledge on the cutaneous manifestations of COVID-19 in children after thorough and critical review of articles published in the literature and from the personal experience of a large panel of paediatric dermatologists in Europe. In Part 1, we discuss one of the first and most widespread cutaneous manifestations of COVID-19, chilblain-like lesions, and in Part 2 we expanded to other manifestations, including erythema multiforme, urticaria and Kawasaki disease-like inflammatory multisystemic syndrome. In this part of the review, we discuss the histological findings of COVID-19 manifestations, and the testing and management of infected children for both COVID-19 and any other pre-existing conditions.
Mots-clé
Adolescent, Antibodies, Monoclonal, Humanized/therapeutic use, COVID-19/complications, COVID-19/diagnosis, COVID-19/pathology, COVID-19 Testing, Child, Dermatologic Agents/therapeutic use, Exanthema/drug therapy, Exanthema/pathology, Exanthema/virology, Humans, Nicolau Syndrome/drug therapy, Nicolau Syndrome/pathology, Nicolau Syndrome/virology, Pityriasis Rosea/pathology, Pityriasis Rosea/virology, Purpura/drug therapy, Purpura/pathology, Purpura/virology, SARS-CoV-2, Skin Diseases, Viral/drug therapy, Skin Diseases, Viral/pathology, Urticaria/drug therapy, Urticaria/pathology, Urticaria/virology
Pubmed
Web of science
Open Access
Oui
Création de la notice
23/11/2020 14:15
Dernière modification de la notice
06/01/2024 8:12
Données d'usage